New study aims to find the best way to biopsy for prostate cancer

NCT ID NCT07460843

Recruiting now Diagnosis Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two prostate biopsy techniques to see which one better detects clinically significant prostate cancer. About 592 men with a suspicious MRI lesion will be randomly assigned to receive either targeted plus perilesional biopsy or targeted plus systematic biopsy. The goal is to find a method that accurately diagnoses important cancers while reducing unnecessary sampling.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: biopsy procedure
What this could lead to: If successful, this could help doctors choose the most accurate and less invasive biopsy method for diagnosing significant prostate cancer.
What could go wrong: This is a diagnostic study, not a treatment trial. Results may not apply to all patients or settings, and the best method may still miss some cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER (DIAGNOSIS)

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.